27th Jul 2020 17:50
ImmuPharma PLC - AIM-listed pharmaceutical company - Clears "important regulatory milestone" in preparation for the new optimised international phase three trial of Lupuzor. ImmuPharma's licensing partner, Avion Pharmaceuticals, submitted a special protocol assessment request to the US Food & Drug Administration. ImmuPharma said the review period for such an assessment request was up to 45 days.
Current stock price: 15.08 pence
Year-to-date change: down 5.8%
By Arvind Bhunjun; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
Immupharma